Physician profile
Anna Elizabeth Kersey
NPI 1881954329
$398,667.52
in general payments reported to CMS, 2019-2025
18 companies · $66K in 2025
The $66K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52K · 2022: $85K · 2023: $113K · 2024: $82K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $212K · Travel and Lodging: $32K · Food and Beverage: $12K · Honoraria: $5,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $212,450.00 |
| Travel and Lodging | $31,702.70 |
| Food and Beverage | $11,950.59 |
| Honoraria | $5,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $389,455.70 | 2021-2025 | |
| Axsome Therapeutics, INC. | $6,240.07 | 2025 | Symbravo |
| Allergan, INC. | $1,914.58 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $179.55 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $167.67 | 2023-2024 | Nuedexta, Rexulti |
| Alexion Pharmaceuticals, INC. | $135.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $127.91 | 2021-2025 | |
| Amgen INC. | $103.63 | 2022-2023 | Evenity |
| Lundbeck LLC | $85.54 | 2022-2024 | Rexulti, Vyepti |
| Biohaven Pharmaceuticals, INC. | $57.49 | 2021 | |
| Pfizer INC. | $45.08 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $36.27 | 2024-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $29.67 | 2025 | |
| Janssen Pharmaceuticals, INC | $21.69 | 2021 | |
| Genentech USA, INC. | $21.11 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $17.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.99 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kersey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.